HomeCompareOCLDY vs ABBV

OCLDY vs ABBV: Dividend Comparison 2026

OCLDY yields 3.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $65.7K in total portfolio value
10 years
OCLDY
OCLDY
● Live price
3.00%
Share price
$12.66
Annual div
$0.38
5Y div CAGR
21.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36.7K
Annual income
$3,542.78
Full OCLDY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OCLDY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCLDYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCLDY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCLDY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCLDY
Annual income on $10K today (after 15% tax)
$255.13/yr
After 10yr DRIP, annual income (after tax)
$3,011.36/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $18,044.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCLDY + ABBV for your $10,000?

OCLDY: 50%ABBV: 50%
100% ABBV50/50100% OCLDY
Portfolio after 10yr
$69.5K
Annual income
$14,157.27/yr
Blended yield
20.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OCLDY
No analyst data
Altman Z
3.2
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCLDY buys
0
ABBV buys
0
No recent congressional trades found for OCLDY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCLDYABBV
Forward yield3.00%3.06%
Annual dividend / share$0.38$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR21.5%40.6%
Portfolio after 10y$36.7K$102.3K
Annual income after 10y$3,542.78$24,771.77
Total dividends collected$14.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OCLDY vs ABBV ($10,000, DRIP)

YearOCLDY PortfolioOCLDY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,065$364.69$11,550$430.00$485.00ABBV
2$12,297$458.20$13,472$627.96$1.2KABBV
3$13,737$578.26$15,906$926.08$2.2KABBV
4$15,432$733.47$19,071$1,382.55$3.6KABBV
5$17,447$935.63$23,302$2,095.81$5.9KABBV
6$19,870$1,201.21$29,150$3,237.93$9.3KABBV
7$22,814$1,553.38$37,536$5,121.41$14.7KABBV
8$26,436$2,025.25$50,079$8,338.38$23.6KABBV
9$30,952$2,664.82$69,753$14,065.80$38.8KABBV
10$36,661$3,542.78$102,337$24,771.77$65.7KABBV

OCLDY vs ABBV: Complete Analysis 2026

OCLDYStock

Orica Limited manufactures and sells commercial explosives and blasting systems in Australia, the United States, and internationally. The company provides 4D bulk explosives systems, packaged explosives, initiating systems, boosters, and seismic systems; and data, reporting, analytics, blasting, contracted, and supplementary services. It also offers automation solutions, including Avatel, a machine equipped with underground development charging system; and secondary breakage and hang up blasting, a tele-remote blasting solution. In addition, the company provides mining chemical products, such as cyanide sparges, emulsifiers, and sodium cyanide, as well as PRO services; digitally enabled benchmarks and insights at various stages of the blasting process; nitrogen fertilizers, which include urea ammonium nitrate and ammonia; and environmental monitoring and consultancy services. Further, it offers chemical and mechanical earth control products, adhesives, and ground support equipment comprising steel bolts and plates, glass fiber reinforced polymer bolts, injectable chemicals and foams, mesh, resin capsules, cementitious grouts and coatings, pumps, soil anchoring systems, ballast bonding polymers, and accessories, as well as engineering services. Additionally, the company provides resources to explore the use of chemical energy in blasting, blasting fundamentals, and properties of explosives and blast design principles; and geotechnical deformation and convergence monitoring solutions. It serves surface coal, surface metal, iron ore, quarrying, underground mining and construction, construction, civil infrastructure, oil and gas, and agriculture markets. The company was founded in 1874 and is headquartered in East Melbourne, Australia.

Full OCLDY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OCLDY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCLDY vs SCHDOCLDY vs JEPIOCLDY vs OOCLDY vs KOOCLDY vs MAINOCLDY vs JNJOCLDY vs MRKOCLDY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.